Sunday, March 3, 2024

Labs For Parkinson’s Disease

Once Registration Is Completed We Will Contact You With Additional Lab Information

Introducing M-Gait, a new lab for Parkinson’s research

Please be advised that the test will require your time and patience. The test kits are a variety of hair, stool, salvia and blood tests. This will ensure sufficient time for tests to be completed and sent to our faculty-doctors.

All required labs charges are included in the cost of your registration. You will not need receive a bill for nor need to submit to insurance.

Is Early Diagnosis Possible

Experts are becoming more aware of symptoms of Parkinsons that precede physical manifestations. Clues to the disease that sometimes show up before motor symptoms and before a formal diagnosis are called prodromal symptoms. These include the loss of sense of smell, a sleep disturbance called REM behavior disorder, ongoing constipation thats not otherwise explained and mood disorders, such as anxiety and depression.

Research into these and other early symptoms holds promise for even more sensitive testing and diagnosis.

For example, biomarker research is trying to answer the question of who gets Parkinsons disease. Researchers hope that once doctors can predict that a person with very early symptoms will eventually get Parkinsons disease, those patients can be appropriately treated. At the very least, these advances could greatly delay progression.

Parkinson’s Disease and Movement Disorders Center

Our center provides compassionate and timely treatment to patients with movement disorders, such as dystonia, ataxia, essential tremor and similar conditions. But our mission goes beyond patient care excellence. By offering educational events and support groups, we empower patients and caregivers to become better partners in their health.

Blood Test May Help Differentiate Parkinsons From Similar Diseases

The American Academy of Neurology is the world’s largest association of neurologists and neuroscience professionals, with 38,000 members. The AAN is dedicated to promoting the highest quality patient-centered neurologic care. A neurologist is a doctor with specialized training in diagnosing, treating and managing disorders of the brain and nervous system such as Alzheimer’s disease, stroke, migraine, multiple sclerosis, concussion, Parkinson’s disease and epilepsy.

Recommended Reading: Parkinson Silverware

Parkinsons Disease And Neurodegeneration Lab

Parkinsons Disease is a chronic debilitating neurodegenerative disorder that currently afflicts > 5 million people globally and is predicted to rapidly increase by 50% in the next 20 years as our population ages. Although predominantly considered a movement disorder, people with PD also experience significant non-motor symptoms including sleep disturbances, olfactory dysfunction, autonomic dysfunction and changes in cognition. Much earlier diagnosis and new treatments are critically needed as at the current late stage of diagnosis, patients have already suffered significant neuronal dysfunction and loss there is no cure and current therapies are only partially effective at treating some of the symptoms, while progression and spread of the disease continues.

The lack of knowledge of the underlying mechanisms responsible for causing PD and its progression is the major impediment to therapeutic advances and a cure. To achieve earlier diagnoses and development of treatments, our research focuses on discovering the cascade of molecular and cellular events that cause the loss of neurons in PD. To accomplish this we are taking a multifaceted approach involving the following:

How Is Parkinson’s Disease Diagnosed

Role of Alpha

Your doctor will ask questions about your symptoms and your past health and will do a neurological exam. This exam includes questions and tests that show how well your nerves are working. For example, your doctor will watch how you move. He or she will check your muscle strength and reflexes and will check your vision.

Your doctor also may check your sense of smell and ask you questions about your mood.

In some cases, your doctor will have you try a medicine for Parkinson’s disease. If that medicine helps your symptoms, it may help the doctor find out if you have the disease.


There are no lab or blood tests that can help your doctor know whether you have Parkinson’s. But you may have tests to help your doctor rule out other diseases that could be causing your symptoms. For example:

  • An MRI or CT scan is used to look for signs of a stroke or brain tumor.
  • Blood tests check for abnormal thyroid hormone levels or liver damage.

Another type of imaging test, called PET, sometimes may detect low levels of dopamine in the brain. These low levels are a key feature of Parkinson’s. But PET scanning isn’t commonly used to evaluate Parkinson’s. That’s because it’s very expensive, not available in many hospitals, and only used experimentally.

Also Check: Weighted Silverware

What Doctors Look For When Diagnosing Parkinsons

Certain physical signs and symptoms noticed by the patient or his or her loved ones are usually what prompt a person to see the doctor. These are the symptoms most often noticed by patients or their families:

  • Shaking or tremor: Called resting tremor, a trembling of a hand or foot that happens when the patient is at rest and typically stops when he or she is active or moving

  • Bradykinesia: Slowness of movement in the limbs, face, walking or overall body

  • Rigidity: Stiffness in the arms, legs or trunk

  • Posture instability: Trouble with balance and possible falls

Once the patient is at the doctors office, the physician:

  • Takes a medical history and does a physical examination.

  • Asks about current and past medications. Some medications may cause symptoms that mimic Parkinsons disease.

  • Performs a neurological examination, testing agility, muscle tone, gait and balance.

Drug Repositioning And Clinical Trials

We investigate the potential to reposition clinically relevant and therapeutically tolerated FDA-approved drugs to treat neurodegenerative diseases. We found that two anti-cancer drugs, including the TKI nilotinib and bosutinib cross the blood barrier, induce autophagic protein clearance and modulate brain and peripheral immunity in pre-clinical models of AD, PD, MND-FTD and other related diseases. These preclinical studies have led to pilot phaseI/II clinical trials to investigate the effects of an escalating oral dose of nilotinib on blood and CSF levels of alpha-synuclein and p-Tau in patients with early PD and PD with LB dementia. These trials will investigate the safety and tolerability of nilotinib and may lead to larger clinical trials that include other disease indications

Department of Neurology

Recommended Reading: Yopd Life Expectancy

Further Testing In Parkinson’s

In other situations, where perhaps the diagnosis is not as clear, younger individuals are affected, or there are atypical symptoms such as tremor affecting both hands or perhaps no tremor at all, further testing may help. For example, imaging can play a role in differentiating between essential tremor and Parkinsons. It can also be important to confirm what is initially a clinical diagnosis of Parkinsons prior to an invasive treatment procedure such as surgical DBS

Parkinson’s Disease Virtual Lab

New biopsy test could predict Parkinson’s Disease

Use liquid chromatography to purify a protein involved in Parkinsons disease to learn more about its causes and evaluate the efficacy of a promising molecule for its treatment using confocal microscopy.

Try Labster’s 30-Day All-Access Trial for Free

Discover one of our 200+ simulations today

  • Features

Read Also: Pfnca Wellness Programs

Safedin Sajo Beqaj Phd Hcld Cc

Dr. Sajo Beqaj is board certified in molecular pathology and genetics and licensed as a Bioanalyst and High Complexity Laboratory Director. He has been practicing as a laboratory director since 2005.

Dr. Beqaj served as a technical director and was part of the initial management team for several well-known laboratories in the clinical lab industry including PathGroup, Nashville, TN DCL Medical Laboratories, Indianapolis, IN, and Pathology, Inc, Torrance, CA. He is currently serving as off-side CLIA laboratory director for BioCorp Clinical Laboratory, Whittier, CA and Health360 Labs, Garden Grove, CA.

Dr. Beqaj received his Ph.D. in Pathology from Wayne State University Medical School, Detroit, Michigan. He performed his post-doctoral fellowship at Abbott Laboratories from 2001-2003 and with Childrens Hospital and Northwestern University from 2003-2005.

Dr. Beqaj has taught in several academic institutions and has published numerous medical textbook chapters and journal articles. He has served as a principal investigator in clinical trials for several well-known pharmaceutical and diagnostic companies such as Roche HPV Athena, Merck HPV vaccine, BD vaginitis panel, Roche CINtec® Histology clinical trials, and has presented various scientific clinical abstracts and presentations.

Ai Speeds Precision Medicine For Parkinsons Disease


  • Over 10 million people worldwide live with Parkinsons disease, including nearly a million Americans.
  • A new study uses AI deep learning that finds cellular disease signatures to help accelerate the discovery of novel therapeutics for Parkinsons.
  • This unique AI deep learning platform solution is not limited to Parkinsons disease. It can be repurposed for other disease signatures.

Artificial intelligence , machine learning, and robotics are accelerating precision medicine for neurodegenerative diseases and brain disorders.

A new study published in Nature Communications reveals a high-throughput screening platform using AI deep learning that finds cellular disease signatures to help accelerate the discovery of novel therapeutics for Parkinsons disease .

To our knowledge, this is the first successful demonstration in which automated, unbiased deep learning-based phenotypic profiling is able to discriminate between primary cells from PD patients and healthy controls, wrote the study authors affiliated with The New York Stem Cell Foundation Research Institute and Google Research.

Over 10 million people worldwide are living with Parkinsons disease, including nearly a million Americans, according to the Parkinsons Foundation, a nonprofit organization.

The scientists report that their automated platform has the ability to simultaneously profile ninety-six primary cell lines with consistent growth rates and minimal variation.

You May Like: Diseases Similar To Parkinsons

How It All Fits Together

Diagnosing Parkinsons disease can be tricky. The process relies heavily on your doctors judgment. In addition, the causes and risk factors of Parkinsons are not entirely clear yet, which contributes to the difficulty in diagnosing this condition.

However, there have been efforts to try and detect this disease earlier. For instance, clinicians have started focusing more on prodromal symptoms, which are early symptoms that appear before movement-related difficulties begin.

These symptoms include:

  • Loss of smell, which can sometimes occur years before other symptoms
  • Chronic constipation, without any other explanation
  • Rapid eye movement behavior disorder, which causes sleep disturbances

Well Help You Develop A Strategy That Is Personalized To You


As part of Parkinson’s Disease Summer School, we have arranged for each participant to have an extensive array of lab tests done prior to the start of the school. These will provide our faculty-doctors the latest insights on your health and enable them to work with you to develop a strategy that is personalized to you.

Read Also: Sam Waterston Tremor

Imaging And Lab Tests

Your doctor may order some imaging tests and laboratory tests. Imaging tests can include computed tomography scans and magnetic resonance imaging scans. Laboratory tests can include blood tests and urine tests.

While these tests and scans will not help diagnose Parkinsons disease, they can help rule out other conditions that have similar symptoms.

Your doctor may also suggest that you get a dopamine transporter scan . This scan requires a single-photon emission computed tomography scanner. It involves an injection of a small amount of a radioactive drug so that your doctor can study the dopamine systems in your brain .

While a DaTscan cannot conclusively prove that you have Parkinsons, it can help confirm your doctors diagnosis and eliminate other conditions.

Is It Parkinson’s Disease Blood Test Might Tell

But new technique needs more study, researchers say

HealthDay Reporter

WEDNESDAY, Feb. 8, 2017 — Measuring a particular blood protein might help doctors easily distinguish Parkinson’s disease from some similar disorders, a new study suggests.

The potential blood test is “not ready for prime time,” Parkinson’s disease experts said. But, it marks progress in the quest for an objective way to diagnose Parkinson’s and similar conditions known as atypical parkinsonian disorders, they noted.

Parkinson’s disease is a movement disorder that affects nearly 1 million people in the United States alone, according to the Parkinson’s Disease Foundation.

The root cause is unclear, but as the disease progresses, the brain loses cells that produce dopamine — a chemical that regulates movement. As a result, people suffer symptoms such as tremors, stiff limbs, and balance and coordination problems that gradually worsen over time.

Right now, there is no blood test, brain scan or other objective measure that can definitively diagnose Parkinson’s, said James Beck, vice president of scientific affairs for the Parkinson’s Disease Foundation.

“In general, Parkinson’s disease is diagnosed with a clinical exam,” Beck explained.

The best person to make that call is a neurologist with expertise in movement disorders, according to Beck.

“But,” he said, “even highly trained doctors initially get it wrong about 10 percent of the time.”

Show Sources


Don’t Miss: Does Sam Waterston Have Parkinsons

Alzheimers Disease And Parkinsons Disease

The primary research goal in Dr. Pasinettis lab is to investigate the biological processes which occur when, during aging, subjects with normal cognitive function convert into the very earliest stages of Alzheimers disease and then to frank dementia. In pioneering research in Dr. Pasinettis lab, Dr. Pasinetti determined that proapoptotic mechanisms may be at play early in the onset of AD, even before overt signs of apoptosis and symptoms. The study indicated that they could be a conditional factor for later neurodegenerative conditions and cognitive impairment. This study is one of several investigations from Dr. Pasinettis lab contributing to the now accepted concept that onset of dementia may be the end result of degenerative conditions that initiated 20-30 years prior to symptoms.

In the last few years, the laboratory has been involved in the identification of novel compounds with preclinical efficacy in reducing A-mediated neuropathology and cognitive dysfunction. Knowledge gained from these investigations will provide the basis for designing full-scale project exploring bioavailability, pharmacokinetics and toxicological characteristics of these lead anti-A oligomerization compounds in animal models and in humans, eventually leading to the development of novel lead compounds for IND-directed preclinical safety assessments and Phase I clinical trials for Alzheimers disease therapy.

How Much Do You Know About Parkinsons Disease

Breakthrough clinical trial could reverse symptoms of Parkinson’s Disease

Parkinsons Disease is suspected of being caused by either genetics or exposure to certain toxins and viruses, but there is no solid proof that these things actively cause PD to develop. Although science currently lacks an explanation for why PD develops, enough research has been conducted to determine how it develops.

PD starts in a part of the mid-brain called substantia nigra. Its a bundle of neurons that are darkly pigmented with melanin. Here, the neurotransmitter dopamine is synthesized. Dopamine is more commonly associated with depression because it is linked with moods and emotions, but it has many functions other than controlling moods. In fact, it plays a big role in movement and motor coordination.

The situation starts to go bad when neurons in the substantia nigra start dying. Without these neurons, dopamine stops being synthesized. Each neuron that dies means there will be less dopamine in the brain. A lack of dopamine then leads to bradykinesia , dyskinesia or tremors, postural issues, and slurred speech the hallmarks of Parkinsons Disease. This is a progressive disease, so the lack of neurons and dopamine gets worse over time.

Read Also: On-off Phenomenon

Nhs Smartwatch For Parkinsons Patients Hailed As Lifechanging

Kinetigraph sends data to doctors so that physiotherapy and prescriptions can be adjusted to meet needs

Thousands of people with Parkinsons disease will be given smartwatches by NHS England so they can be treated effectively from home.

The Parkinsons Kinetigraph contains sensors that monitor the wearers activity, and buzzes to remind them to take medication.

Data is sent to doctors to help detect excessive movement, immobility and sleep disturbances, allowing practitioners to adjust physiotherapy and prescriptions according to the patients needs.

John Whipps, who was diagnosed with Parkinsons in 2007 and was one of hundreds of patients who took part in a pilot scheme with the watch, said: The problem is that Parkinsons changes from day to day, and even throughout each day.

Under the traditional system, you have to remember all your concerns and symptoms between visits, ensure you can attend the appointment, have the stress of getting to hospital on time, and then remember to tell your consultant how you are.

He said of the watch: It really gives you confidence as you know it gives accurate recordings, and you dont need to rely so much on your own perception. As the non-motor symptoms begin to be recorded digitally, they will also help doctors track those and inform the healthcare team.

The NHS England chief executive, Amanda Pritchard, said the watch would help improve the quality of life for 120,000 Parkinsons patients while improving efficiency in the NHS.

Simple Blood Tests For Parkinson’s Disease Derived From Genome

The diagnosis of Parkinson’s disease relies on expert opinion. Autopsy studies, however, have demonstrated that even experienced neurologists misdiagnose Parkinson’s disease in about a quarter out of a hundred cases. Diagnostic accuracy at disease onset, when neuroprotective treatment is anticipated to be most effective, is even lower. Thus, there is a crucial need for biomarkers that are disease-specific and which precisely identify early disease stages.

Traditional studies of blood from Parkinson’s disease patients have analyzed expression levels of one gene or gene product at a time. We plan to take advantage of ‘gene chip’ technology allowing expression analysis of up to 22,000 genes on a single glass slide, known as microarray. We hypothesize that a comparison of the gene chip analyses of blood samples from Parkinson’s disease patients and normal controls or patients with other neurological diseases will identify a set of signature genes with characteristic expression in patients with Parkinson’s disease. These key genes will provide a ‘molecular fingerprint’ of Parkinson’s disease in blood.

Recommended Reading: Does Vitamin B12 Help Parkinson’s

Single Photon Emission Computed Tomography

In single photon emission computed tomography , a gamma ray-emitting radioactive isotope is tagged to a molecule of interest , which is given to the person with by intravenous injection. The labelled cocaine derivatives 123I–CIT and 123I-FP-CIT tropane) have most commonly been used, although only the latter is licensed in the UK. These label the presynaptic dopamine re- site and thus the presynaptic neurone, which can be visualised in two-dimensional images. These demonstrate normal uptake in the caudate and putamen in controls and in people with essential tremor, neuroleptic-induced parkinsonism or psychogenic parkinsonism, but reduced uptake in those with PD, PD with dementia, or .

How useful is SPECT in discriminating from alternative conditions?

Popular Articles
Related news